Fujisawa, Shin
Ueda, Yasunori
Usuki, Kensuke
Kobayashi, Hajime
Kondo, Eisei
Doki, Noriko
Nakao, Takafumi
Kanda, Yoshinobu
Kosugi, Nobuharu
Kosugi, Hiroshi
Kumagai, Takashi
Harada, Hiroshi
Shikami, Masato
Maeda, Yasuhiro
Sakura, Toru
Inokuchi, Koiti
Saito, Akio
Nawa, Yuichiro
Ogasawara, Masahiro
Nishida, Junji
Kondo, Takeshi
Yoshida, Chikashi
Kuroda, Hiroyuki
Tabe, Yoko
Maeda, Yoshinobu
Imajo, Kenji
Kojima, Kensuke
Morita, Satoshi
Komukai, Sho
Kawaguchi, Atsushi
Sakamoto, Junichi
Kimura, Shinya
Article History
Received: 4 September 2018
Accepted: 5 November 2018
First Online: 12 November 2018
Compliance with ethical standards
:
: S. Fujisawa has received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, and Otsuka Pharmaceuticals and research funding form Pfizer and Novartis. K. Usuki has received honoraria from MSD K.K, Sumitomo Dainippon Pharma, Pfizer Japan, Celgene Corporation, Novartis, Ono Pharmaceutical, Takeda Pharmaceuticals, Chugai Pharmaceutical, Nippon Shinyaku, and Mochida Pharmaceutical and research funding from MSD K.K, Sumitomo Dainippon Pharma, Pfizer Japan, Celgene Corporation, Astellas Pharma, Otsuka, Kyowa Kirin, Glaxo Smithkline K.K, Sanofi K.K, Shire Japan, Symbio Pharmaceuticals Limited, Daiichi Sankyo, Boehringer-Ingelheim Japan, and Janssen Pharmaceutical K,K. Y. Kanda has received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, and Otsuka Pharmaceuticals and research funding from Pfizer and Otsuka Pharmaceuticals. T. Kumagai has held an advisory role for Novartis and has received honoraria from Bristol-Myers Squibb, Pfizer, and Otsuka. K. Inokuchi has held an advisory role for Novartis and Otsuka Pharmaceutical and has received honoraria from Bristol-Myers Squibb, Celgene, Novartis, and Pfizer and research funding from Bristol-Myers Squibb. T. Kondo has received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, Otsuka Pharmaceuticals, and Celgene and research funding Bristol-Myers Squibb. C. Yoshida has received honoraria from Bristol-Myers Squibb, Pfizer, and Otsuka Pharmaceuticals. Y. Maeda has received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, Otsuka Pharmaceuticals, and Celgene and research funding from Bristol-Myers Squibb, Pfizer, and Otsuka Pharmaceuticals. K. Kojima has held an advisory role for Janssen Asia Pacific (Singapore) and has received research funding from Janssen Global (USA), and PTC Therapeutics (USA). S. Morita has received honoraria from Bristol-Myers Squibb, and Pfizer. J. Sakamoto has held an advisory role for Takeda and has received honoraria from Chugai, Nihon Kayaku, and Tsumura. S. Kimura has received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, and Otsuka Pharmaceuticals and research funding Bristol-Myers Squibb, Novartis, Pfizer, Otsuka Pharmaceuticals, and Ohara pharmaceutical. All remaining authors declare no conflicts of interest.